Passey C - Search Results

1

The Clinical Pharmacology of Elotuzumab.

Passey C, Sheng J, Mora J, Tendolkar A, Robbins M, Dodge R, Roy A, Bello A, Gupta M. Passey C, et al. Clin Pharmacokinet. 2018 Mar;57(3):297-313. doi: 10.1007/s40262-017-0585-6. Clin Pharmacokinet. 2018. PMID: 28779463 Review.

2

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.

Gibiansky L, Passey C, Roy A, Bello A, Gupta M. Gibiansky L, et al. Among authors: passey c. J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):243-57. doi: 10.1007/s10928-016-9469-x. Epub 2016 Mar 18. J Pharmacokinet Pharmacodyn. 2016. PMID: 26993283

3

Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.

Passey C, Darbenzio R, Jou YM, Lynch M, Gupta M. Passey C, et al. Cancer Chemother Pharmacol. 2016 Dec;78(6):1237-1244. doi: 10.1007/s00280-016-3182-8. Epub 2016 Oct 28. Cancer Chemother Pharmacol. 2016. PMID: 27796540

4

An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.

Passey C, Mora J, Dodge R, Gibiansky L, Sheng J, Roy A, Bello A, Gupta M. Passey C, et al. AAPS J. 2017 Mar;19(2):557-567. doi: 10.1208/s12248-016-0033-9. Epub 2017 Jan 9. AAPS J. 2017. PMID: 28070715

5

Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.

Passey C, Suryawanshi S, Sanghavi K, Gupta M. Passey C, et al. AAPS J. 2018 Feb 26;20(2):35. doi: 10.1208/s12248-018-0194-9. AAPS J. 2018. PMID: 29484520 Review.

6

Methods for determining key components in a mathematical model for tumor-immune dynamics in multiple myeloma.

Gallaher J, Larripa K, Renardy M, Shtylla B, Tania N, White D, Wood K, Zhu L, Passey C, Robbins M, Bezman N, Shelat S, Jay Cho H, Moore H. Gallaher J, et al. Among authors: passey c. J Theor Biol. 2018 Dec 7;458:31-46. doi: 10.1016/j.jtbi.2018.08.037. Epub 2018 Aug 30. J Theor Biol. 2018. PMID: 30172689

7

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.

Gibiansky L, Passey C, Voellinger J, Gunawan R, Hanley WD, Gupta M, Winter H. Gibiansky L, et al. Among authors: passey c. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1358-1370. doi: 10.1002/psp4.12850. Epub 2022 Aug 6. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35932175 Free PMC article.

8

Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors.

Passey C, Voellinger J, Gibiansky L, Gunawan R, Nicacio L, Soumaoro I, Hanley WD, Winter H, Gupta M. Passey C, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1262-1273. doi: 10.1002/psp4.13007. Epub 2023 Jul 26. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37496366 Free PMC article.

9

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.

Yonemori K, Kuboki Y, Hasegawa K, Iwata T, Kato H, Takehara K, Hirashima Y, Kato H, Passey C, Buchbjerg JK, Harris JR, Andreassen CM, Nicacio L, Soumaoro I, Fujiwara K. Yonemori K, et al. Among authors: passey c. Cancer Sci. 2022 Aug;113(8):2788-2797. doi: 10.1111/cas.15443. Epub 2022 Jun 15. Cancer Sci. 2022. PMID: 35633184 Free PMC article. Clinical Trial.

10

Dosing equation for tacrolimus using genetic variants and clinical factors.

Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Passey C, et al. Br J Clin Pharmacol. 2011 Dec;72(6):948-57. doi: 10.1111/j.1365-2125.2011.04039.x. Br J Clin Pharmacol. 2011. PMID: 21671989 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters